The PROPHY-VAP Trial: Ceftriaxone to Prevent VAP in Patients with Acute Brain Injury
REBEL EM
FEBRUARY 29, 2024
1, 2 Its occurrence often portends worse outcomes in intubated patients, whose projected hospital course was already tenuous. Stratified by center (different hospital practices may affect results) and GCS (<8 or ≥8) (higher VAP risk inherent to lower GCS). 4, 8 Paper: Dahyot-Fizelier, C.,
Let's personalize your content